Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.53 |
| ▸ | CA9 | Q16790 | 9/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10529566 | 0.83 | HSD17B3 (0.38) | CA12CA9CA2NR4A2 | |
| SCHEMBL10352783 | 0.82 | CCR5 (0.39) | CA12CA9TDP1CCR5KDM4E | |
| SCHEMBL25213039 | 0.81 | CFTR (0.48) | CA12CA9TDP1CA2KDM4E | |
| SCHEMBL7911204 | 0.79 | CA12 (0.50) | CA12CA9CA2KDM4EHPGD | |
| SCHEMBL31090834 | 0.79 | CA12 (0.50) | CA12CA9CA2KDM4EHPGD | |
| SCHEMBL10439343 | 0.76 | KDM4E (0.41) | CA12CA9CA2KDM4E | |
| SCHEMBL7216486 | 0.76 | CA12 (0.41) | CA12CA9CA2POLB | |
| SCHEMBL947578 | 0.75 | KDM4E (0.43) | CA12CA9CA2KDM4E | |
| SCHEMBL5694225 | 0.75 | CA12 (0.44) | CA12CA9CA2 | |
| SCHEMBL7218351 | 0.75 | CA12 (0.52) | CA12CA9TDP1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CA12 4119/4885CA9 2868/4885TDP1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.